Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $94.3K fell 81.1% year over year, behind the -70.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 54.3% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -81.1% toward the trailing-twelve-month pace of -70.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.42M USD
- Year-over-year change
- -66.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.42M | -66.7% |
| FY2024 | 2024-12-31 | 4.27M | -18.8% |
| FY2023 | 2023-12-31 | 5.25M | +701.3% |
| FY2022 | 2022-12-31 | 655.35K | +142.1% |
| FY2021 | 2021-12-31 | (1.56M) | — |
Other Income / Expenses vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -70.6% is the 6th highest of 10, against a peer median of -51.5%.
- Over three fiscal years its annual growth of +29.4% compares with a peer median of +7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.41M USD | +109.1% | — | — |
| LTM Mar 2026 | $7.39M USD | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $2.64M USD | -79.4% | — | 1.2% | |
| LTM Mar 2026 | $2M USD | +133.4% | -14.1% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $1.99M USD | +5.2% | — | 24812.5% |
| LTM Mar 2026 | $1.86M USD | +124.8% | — | 372.3% | |
| LTM Mar 2026 | $1.43M USD | — | -50.1% | 155.2% | |
| LTM Mar 2026 | $1.01M USD | -70.6% | +29.4% | — | |
| LTM Mar 2026 | -CHF 1.47M CHF | -268.3% | — | 39.8% | |
| LTM Mar 2026 | -$23.45M USD | -215.6% | — | 34.4% | |
| LTM Mar 2026 | -$129.21M USD | -2023.6% | +28.2% | — | |
| Peer median (excluding ALDX) | — | -51.5% | +7.1% | 97.5% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
| Selling, General & Admin | 11.28M | 15.37M | 13.34M | 11.89M | 9.6M |
| Operating Expenses | 56.22M | 62.68M | 42.79M | 60.12M | 35.27M |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| EBITDA | (55.77M) | (60.07M) | (35.21M) | (53.68M) | (31.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (56.22M) | (62.68M) | (42.79M) | (60.12M) | (35.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 185.36K | 2.35M | 7.32M | 6.19M | 3.32M |
| Interest Expense | 1.74M | 1.69M | 2.07M | 1.93M | 1.91M |
| Other Income / Expenses | (1.56M) | 655.35K | 5.25M | 4.27M | 1.42M |
| Income Before Tax | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| EPS (Diluted) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| Weighted Avg Shares | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
| Weighted Avg Shares (Diluted) | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.